Product
F0002-ADC
1 clinical trial
1 indication
Indication
CD30+ Hematologic MalignanciesClinical trial
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.Status: , Estimated PCD: 2022-12-01